Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.83 USD | -5.85% | -6.58% | +11.55% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- For the past twelve months, EPS forecast has been revised upwards.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The firm trades with high earnings multiples: 18.7 times its 2024 earnings per share.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.55% | 233M | C+ | ||
+4.09% | 43.84B | B | ||
+46.73% | 41.25B | A | ||
+9.45% | 41.68B | B- | ||
-10.92% | 27.04B | C | ||
+9.32% | 25.53B | B- | ||
-24.87% | 18.18B | B | ||
+29.70% | 12.29B | C+ | ||
+1.28% | 12.29B | C+ | ||
+7.78% | 11.15B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PBYI Stock
- Ratings Puma Biotechnology, Inc.